In Vitro Evaluation of Sparfloxacin Activity and Spectrum Against 24,940 Pathogens Isolated in the United States and Canada, the Final Analysis

This publication has 30 references indexed in Scilit:

• Comparative in vitro assessment of sparfloxacin activity and spectrum using results from over 14,000 pathogens isolated at 190 medical centers in the USA
  Diagnostic Microbiology and Infectious Disease, 1997
• In vitro activity of BAY 12-8039, a novel 8-methoxyquinolone, compared to activities of six fluoroquinolones against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis
  Antimicrobial Agents and Chemotherapy, 1997
• Comparative safety and efficacy of sparfloxacin in the treatment of acute exacerbations of chronic obstructive pulmonary disease: A double-blind, randomised, parallel, multicentre study
  Journal of Antimicrobial Chemotherapy, 1996
• Sparfloxacin for the treatment of community-acquired pneumonia: a pooled data analysis of two studies
  Journal of Antimicrobial Chemotherapy, 1996
• In-vitro activity of sparfloxacin in comparison with currently available antimicrobials against respiratory tract pathogens
  Journal of Antimicrobial Chemotherapy, 1996
• National survey of the in vitro spectrum of piperacillin-tazobactam tested against more than 40,000 aerobic clinical isolates from 236 medical centers
  Diagnostic Microbiology and Infectious Disease, 1995
• Emergence of drug-resistant pneumococcal infections in the United States
  JAMA, 1994
• Incomplete cross-resistance between ciprofloxacin and sparfloxacin In staphylococci, with a note on selection pressure due to clinical use of ciprofloxacin
  Journal of Antimicrobial Chemotherapy, 1993
• Rapid Development of Ciprofloxacin Resistance in Methicillin-Susceptible and -Resistant Staphylococcus aureus
  The Journal of Infectious Diseases, 1991
• Tetracycline and erythromycin resistance among clinical isolates of Branhamella catarrhalis
  Antimicrobial Agents and Chemotherapy, 1989